Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III Estrogen Receptor positive and HER2 negative breast cancer resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
- Citation:
- Cancer Res vol 81 (4 Supplement) GS4-05
- Meeting Instance:
- SABCS 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3910
- Pharmas:
- Genentech, AstraZeneca
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868 (NRG);
- Corr. Author:
- Authors:
- Cynthia X. Ma Vera Suman A. Marilyn Leitch Souzan Sanati Kiran Vij Gary W. Unzeitig Jeremy Hoog Mark Watson Olwen Hahn Joseph Guenther Abigail Caudle Erika Crouch Horacio Maluf Amy Tiersten Monica Mita Wajeeha Razaq Tina J. Hieken Yang Wang Travis Dockter Jo Anne Zujewski Anna Weiss Kelly Hunt Clifford Hudis Eric P. Winer Matthew J. Ellis Lisa A. Carey Ann H. Partridge
- Networks:
- CA016, KY015, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC007, LAPS-NY016, LAPS-OK003, LAPS-TX011, LAPS-TX035, NEWMEXICO, NY021, NY167, TX041, TX190
- Study
- Alliance-A011106
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: